Tenaya Therapeutics announces promising data from MyPEAK-1 phase 1b/2 clinical trial of TN-201 to treat MYBPC3-...
Tenaya Therapeutics, Inc, a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, has announced encouraging early data from the first cohort …